Article
Oncology
K. E. Francis, S. Kim, M. Friedlander, V Gebski, I Ray-Coquard, A. Clamp, R. T. Penson, A. Oza, T. Perri, T. Huzarski, C. Martin-Lorente, S. C. Cecere, N. Colombo, B. Ataseven, K. Fujiwara, G. Sonke, I Vergote, E. Pujade-Lauraine, J-W Kim, C. K. Lee
Summary: Using data from the SOLO2 trial, this study evaluated the impact of dose alterations on survival outcomes of olaparib treatment and identified baseline characteristics associated with dose alteration.
ANNALS OF ONCOLOGY
(2022)
Review
Oncology
Qian Chen, Xiaoli Li, Zhen Zhang, Tong Wu
Summary: Olaparib treatment for recurrent platinum-sensitive ovarian cancer shows better efficacy and longer overall survival compared to the control group, but comes with a higher risk of adverse reactions.
FRONTIERS IN ONCOLOGY
(2022)
Article
Endocrinology & Metabolism
Zhenli Tang, Demei Xin, Wei Liu, Bing Yan, Rui Liu
Summary: This study aimed to compare the clinical effects of targeted treatments with Nilaparib and Olaparib on recurrent ovarian cancer. A total of 98 patients were enrolled and randomly assigned to two groups. The results showed that Nilaparib had better therapeutic effect and decreased serum level of CA125 compared to Olaparib, suggesting that targeted treatment with Nilaparib was more effective for recurrent ovarian cancer.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2023)
Article
Pharmacology & Pharmacy
Yanting Wang, Di Du, Jun Yang, Alan H. Lau, Yuanyuan Dai, Wangjun Qin, Ning Li, Guohui Li
Summary: A pharmacist-led olaparib follow-up program was established for ovarian cancer patients. The study found that the types of adverse drug reactions (ADRs) were similar to previous clinical trial observations, and identified drug-related problems for which pharmacists provided suggestions.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Shun Endo, Shogo Shigeta, Hideki Tokunaga, Takanori Shimizu, Junko Hasegawa-Minato, Chiaki Hashimoto, Masumi Ishibashi, Tomoyuki Nagai, Naomi Shiga, Muneaki Shimada, Nobuo Yaegashi
Summary: Identification of potential clinical biomarkers for olaparib sensitivity in patients with recurrent ovarian cancer, and validation of the effectiveness of olaparib.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
(2022)
Article
Obstetrics & Gynecology
Angela Cho, Jeong-Yeol Park, Shin-Wha Lee, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim
Summary: Olaparib maintenance therapy is effective and safe in patients with BRCA-mutated recurrent ovarian cancer in clinical practice. Factors such as most recent PFI, response to the last platinum-based chemotherapy, and number of previous chemotherapy lines are associated with PFS in these patients.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2021)
Article
Genetics & Heredity
Dolores Gallardo-Rincon, Edgar Montes-Servin, Gabriela Alamilla-Garcia, Elizabeth Montes-Servin, Antonio Bahena-Gonzalez, Lucely Cetina-Perez, Flavia Morales Vasquez, Claudia Cano-Blanco, Jaime Coronel-Martinez, Ernesto Gonzalez-Ibarra, Raquel Espinosa-Romero, Rosa Maria Alvarez-Gomez, Abraham Pedroza-Torres, Denisse Castro-Eguiluz
Summary: In this study, it was found that Mexican OC patients with the BRCA1-Del ex9-12 mutation treated with olaparib showed a significant increase in PFS compared to other BRCA mutations, regardless of the treatment line.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Shannon N. Westin, Marilyne Labrie, Jennifer K. Litton, Aurora Blucher, Yong Fang, Christopher P. Vellano, Joseph R. Marszalek, Ningping Feng, XiaoYan Ma, Allison Creason, Bryan Fellman, Ying Yuan, Sanghoon Lee, Tae-Beom Kim, Jinsong Liu, Anca Chelariu-Raicu, Tsun Hsuan Chen, Nashwa Kabil, Pamela T. Soliman, Michael Frumovitz, Katheleen M. Schmeler, Amir Jazaeri, Karen H. Lu, Rashmi Murthy, Larissa A. Meyer, Charlotte C. Sun, Anil K. Sood, Robert L. Coleman, Gordon B. Mills
Summary: This study aimed to confirm the recommended phase II dose for the combination of olaparib and capivasertib in multiple cancers, and evaluate molecular markers of response and resistance. Promising responses, especially in endometrial cancer, were observed among the 38 enrolled patients. Therapy resistance was associated with specific signaling pathways and metabolic factors.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Kazuho Nakanishi, Takashi Yamada, Gen Ishikawa, Shunji Suzuki
Summary: This study identified that for patients with platinum-sensitive recurrent ovarian cancer, NLPN scores lower than 7.51 are associated with a more favorable outcome, and there is a clear correlation between dose reduction of olaparib and recurrence.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Nichole A. Martin, Mina Hanna, Christopher Ehret, Gladys Asiedu, Aminah Jatoi
Summary: The study reveals the positive attitude of patients towards olaparib, with a willingness to take it long term and a strong emphasis on adherence, despite having endured a long cancer journey.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, David Cella, William P. Tew, Noelle G. Cloven, Carolyn Y. Muller, David P. Bender, Richard G. Moore, David P. Michelin, Steven E. Waggoner, Melissa A. Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman
Summary: This study evaluated the activity of two all-oral nonplatinum alternatives (olaparib or olaparib/cediranib) versus platinum-based chemotherapy in platinum-sensitive ovarian cancer. The results showed that olaparib/cediranib did not improve progression-free survival (PFS) compared with chemotherapy and resulted in reduced patient-reported outcomes (PROs). However, both olaparib and olaparib/cediranib had significant clinical activity in patients with a germline BRCA mutation.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
K. E. Broekman, M. Van Kruchten, H. Van Tinteren, C. Sessa, M. Jalving, A. K. L. Reyners
Summary: According to ESMO-MCBS scores, only a few licensed systemic treatments for recurrent ovarian cancer show substantial clinical benefit, including platinum-based chemotherapy with paclitaxel in platinum-sensitive settings and the addition of bevacizumab to chemotherapy in platinum-resistant settings. Overall survival benefit trials are rare.
Article
Oncology
Jung-Min Lee, Richard G. Moore, Sharad Ghamande, Min S. Park, John P. Diaz, Julia Chapman, James Kendrick, Brian M. Slomovitz, Krishnansu S. Tewari, Elizabeth S. Lowe, Tsveta Milenkova, Sanjeev Kumar, Mike Dymond, Jessica Brown, Joyce F. Liu
Summary: The efficacy, safety, and tolerability of cediranib plus olaparib were investigated in patients with platinum-resistant recurrent ovarian cancer. The combination therapy showed some clinical activity in heavily pretreated, non-gBRCAm patients, highlighting the need for further biomarker studies.
CLINICAL CANCER RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Brigida Anna Maiorano, Mauro Francesco Pio Maiorano, Evaristo Maiello
Summary: Ovarian cancer is a common and highly lethal cancer in women. Poly (ADP-ribose) polymerase inhibitors have significantly impacted the treatment of metastatic ovarian cancer, and olaparib is the first PARPi developed for this disease. This review summarizes the pharmacokinetic and pharmacodynamic properties of olaparib, its use in special patient populations, and the efficacy and safety of clinical trials leading to its approval. Future developments of olaparib are also discussed.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, Aneta Rogalska
Summary: This study demonstrated that the combination treatment of olaparib and metformin had a significant inhibitory effect on HR-proficient ovarian cancer cells, inducing apoptosis by increasing ROS levels. The synergistic effect was observed in cells with mutant or null p53, providing a new approach for the treatment of gynecologic cancers. The results support the use of metformin to enhance the sensitivity of EOC to olaparib therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Elena Giudice, Vanda Salutari, Caterina Ricci, Camilla Nero, Maria Vittoria Carbone, Lucia Musacchio, Viola Ghizzoni, Maria Teresa Perri, Floriana Camarda, Francesca Tronconi, Domenica Lorusso, Giovanni Scambia
Summary: Several new agents are being evaluated to personalize EC treatment based on specific molecular profiles in the adjuvant, advanced, and recurrent settings. Clinical trials investigating the impact of molecular classification have yielded encouraging results. EC should no longer be considered as a single tumor entity susceptible to a single treatment modality, but rather as four distinct types requiring tailored treatments.
EXPERT OPINION ON PHARMACOTHERAPY
(2023)
Article
Oncology
Fara Braso-Maristany, Gaia Griguolo, Nuria Chic, Tomas Pascual, Laia Pare, Julia Maues, Patricia Galvan, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martinez-Saez, Mercedes Marin-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Munoz, Esther Sanfeliu, Blanca Gonzalez, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, PierFranco Conte, Aleix Prat, Valentina Guarneri
Summary: This study evaluated the association between ERBB2 mRNA expression levels and response and survival following T-DM1 treatment. The results showed that ERBB2 mRNA expression levels were associated with better survival and treatment response.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Article
Oncology
Mario Caccese, Anna Maria Saieva, Valentina Guarneri, Sara Lonardi, Massimo Cacco, Vanna Chiarion Sileni, Michele Gottardi, Eleonora Mioranza, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel, Patrizia Benini
Summary: Routine testing for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients during treatment did not appear to be cost-effective. Out of 2439 cancer patients screened, only 2.17% tested positive, and 92.5% had their cancer treatment discontinued as a precaution.
Article
Oncology
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Sara Balduzzi, Roberto Damico, Pierfranco Conte, Valentina Guarneri
Summary: The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. In this analysis of the ShortHER trial, 784 patients with HR-positive/HER2-positive BC were included, and it was found that AI treatment was associated with significantly better disease-free survival (DFS) compared to TAM or TAM-AI treatment. Among premenopausal patients aged <= 45 years, the use of GnRHa was also associated with longer DFS.
Article
Oncology
Anna-Maria Lazaratos, Sarah M. Maritan, Andrea Quaiattini, Amelie Darlix, Ivica Ratosa, Emanuela Ferraro, Gaia Griguolo, Valentina Guarneri, Alessia Pellerino, Silvia Hofer, William Jacot, Hans-Joachim Stemmler, Marcel P. H. van den Broek, Nika Dobnikar, Francois Panet, Zubin Lahijanian, Aki Morikawa, Andrew D. Seidman, Riccardo Soffietti, Lawrence Panasci, Kevin Petrecca, April A. N. Rose, Nathaniel Bouganim, Matthew Dankner
Summary: Intrathecal administration of HER2-targeted therapy does not provide additional benefits for HER2+ breast cancer patients with leptomeningeal metastases compared to oral or intravenous treatment regimens. However, treatment with trastuzumab-deruxtecan may lead to prolonged overall survival for these patients, but further research is needed to confirm this.
Review
Oncology
F. Miglietta, A. Fabi, D. Generali, M. V. Dieci, G. Arpino, G. Bianchini, S. Cinieri, P. F. Conte, G. Curigliano, M. De Laurentiis, L. Del Mastro, S. De Placido, A. Gennari, F. Puglisi, A. Zambelli, F. Perrone, V. Guarneri
Summary: Triple-negative metastatic breast cancer (TN-mBC) is the most challenging scenario within the framework of metastatic breast cancer. Although chemotherapy is still the main treatment modality, there have been advancements in the development of effective agents for TN-mBC.
CANCER TREATMENT REVIEWS
(2023)
Review
Oncology
Giulia Pasello, Daniela Scattolin, Laura Bonanno, Francesca Caumo, Andrea Dell 'Amore, Elena Scagliori, Mariaenrica Tin, Fiorella Calabrese, Gaetano Benati, Matteo Sepulcri, Cristina Baiocchi, Michele Milella, Federico Rea, Valentina Guarneri
Summary: Lung cancer is the leading cause of cancer-related death worldwide due to the lack of a screening program. Trials on low-dose computed tomography (LDCT) screening in high-risk populations have shown a significant reduction in lung cancer mortality. However, there is heterogeneity in terms of screening criteria, methods, and follow-up. Active screening programs will likely lead to more early-stage NSCLC diagnoses. Innovative drugs and therapies have improved resection rates and survival in the perioperative setting. This review summarizes the evidence and discusses future perspectives in LC screening and perioperative treatment.
CANCER TREATMENT REVIEWS
(2023)
Article
Obstetrics & Gynecology
Caterina Barbieri, Ottavia Amato, Anna Chiara Cattelan, Loris Marin, Alessandra Andrisani, Carlo Saccardi, Tommaso Giarratano, Giovanni Faggioni, Elisabetta Di Liso, Carlo Alberto Giorgi, Eleonora Mioranza, Cristina Falci, Grazia Maria Vernaci, Roberto Tozzi, Valentina Guarneri, Maria Vittoria Dieci
Summary: One main issue in young breast cancer patients is the impact of oncological treatments on fertility. The COVID-19 pandemic has affected the integration of fertility procedures into clinical practice. This study aims to describe the time-related evolution in addressing oncofertility issues.
CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY
(2023)
Article
Oncology
Carmine Valenza, Dario Trapani, Sara Gandini, Caterina Sposetti, Luca Boscolo Bielo, Antonio Marra, Tommaso Giarratano, Diletta Favero, Laura Cortesi, Luca Moscetti, Mirco Pistelli, Rossana Berardi, Alberto Zambelli, Matteo Lambertini, Lucia Del Mastro, Valentina Guarneri, Claudio Vernieri, Giuseppe Curigliano
Summary: Patients with germinal BRCA pathogenic variant and advanced breast cancer may have enhanced sensitivity to platinum-based chemotherapy and PARP inhibitors. However, the sensitivity and resistance to these treatments may partially overlap. The impact of prior exposure to PARP inhibitors/platinum-based chemotherapy on tumor response to subsequent treatment remains unclear.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Lucia Musacchio, Margherita Turinetto, Laura Arenare, Michele Bartoletti, Daniela Califano, Valentina Tuninetti, Claudia Marchetti, Gennaro Cormio, Vera Loizzi, Carmela Pisano, Vanda Salutari, Giorgio Valabrega, Domenico Priolo, Sabrina Chiara Cecere, Jole Ventriglia, Francesco Raspagliesi, Francesco Perrone, Anna Fagotti, Domenica Lorusso, Giovanni Scambia, Sandro Pignata
Summary: The study aimed to explore the efficacy of Bevacizumab (Bev) in the treatment of advanced low grade serous ovarian cancer (LGSOC) in both first-line and recurrent settings. The results showed that Bev combined with chemotherapy significantly improved progression-free survival (PFS) in LGSOC patients compared to chemotherapy alone, both in first-line and recurrent treatments. These findings suggest that Bev may be an effective treatment option for LGSOC.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Lucia Musacchio, Serena Boccia, Claudia Marchetti, Angelo Minucci, Floriana Camarda, Chiara Cassani, Jole Ventriglia, Vanda Salutari, Viola Ghizzoni, Elena Giudice, Maria Teresa Perri, Maria Vittoria Carbone, Caterina Ricci, Sandro Pignata, Anna Fagotti, Giovanni Scambia, Domenica Lorusso
Summary: This study evaluated the differences in survival outcomes in patients with BRCA variants of unknown significance, mutated, and wild type relapsed ovarian cancer treated with PARPi. The results showed that patients with BRCA mutations had significantly longer progression-free survival compared to those with BRCA wild type or variants of unknown significance.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Summary: In 428 patients with HR+/HER2- advanced breast cancer, HER2-low status was found to be independently associated with worse progression-free survival (PFS) and overall survival (OS) compared to HER2-0 status. These findings suggest that HER2-low status could serve as a new prognostic biomarker in this clinical setting.
Article
Oncology
L. Cortesi, M. Venturelli, G. Cortesi, F. Caggia, A. Toss, E. Barbieri, U. De Giorgi, V. Guarneri, A. Musolino, E. De Matteis, A. Zambelli, G. Bisagni, M. Dominici
Summary: In this clinical trial, the efficacy and safety of pembrolizumab plus carboplatin in treating first-line visceral disease BRCA-related luminal breast cancer were investigated. The primary aim of achieving an overall response rate >70% was not met, but further investigation is needed.
Article
Oncology
Nicola Normanno, Antonella De Luca, Riziero Esposito Abate, Alessandro Morabito, Michele Milella, Fabrizio Tabbo, Giuseppe Curigliano, Cristina Masini, Paolo Marchetti, Giancarlo Pruneri, Valentina Guarneri, Giovanni L. Frassineti, Gianpiero Fasola, Vincenzo Adamo, Bruno Daniele, Rossana Berardi, Florinda Feroce, Evaristo Maiello, Carmine Pinto
Summary: The Italian Register of Actionable Mutations is a multicentric observational study that collects next-generation sequencing data of patients with advanced solid tumors. The study identifies the rate of actionable mutations and highlights the utility of comprehensive genomic profiling in selected cancer patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Daniela Scattolin, Elena Scagliori, Antonio Scapinello, Alberto Fantin, Valentina Guarneri, Giulia Pasello
Summary: This is a case report on the use of selpercatinib in patients with RET fusion-positive non-small cell lung cancer. The patient developed severe gastrointestinal toxicity during treatment, leading to treatment interruption and dose reduction.
FRONTIERS IN ONCOLOGY
(2023)